Estudo randomizado | Efeitos da profilaxia 1 vez/semana com efanesoctocog alfa em pacientes com hemofilia A grave

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Once-Weekly Efanesoctocog Alfa Beneficial in Severe Hemophilia A – HealthDay

Comentário no Twitter com um resumo em vídeo

Efanesoctocog alfa is a new class of factor VIII replacement for hemophilia A that has a longer half-life than other factor VIII products, thus allowing once-weekly dosing. New research findings are summarized in a short video. https://t.co/YuXzifUh8m pic.twitter.com/POCAAfeEni

— NEJM (@NEJM) January 27, 2023